Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Fatigue and HRAS[original query] |
---|
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Apr 18 (7): 2056-65. Hayes D Neil, Lucas Amy S, Tanvetyanon Tawee, Krzyzanowska Monika K, Chung Christine H, Murphy Barbara A, Gilbert Jill, Mehra Ranee, Moore Dominic T, Sheikh Arif, Hoskins Janelle, Hayward Michele C, Zhao Ni, O'Connor Wendi, Weck Karen E, Cohen Roger B, Cohen Ezra E |
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. European journal of cancer (Oxford, England : 1990) 2018 May 97 7-15. Cavalieri S, Perrone F, Miceli R, Ascierto P A, Locati L D, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi |
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jul . Lee Hye Won, Sa Jason K, Gualberto Antonio, Scholz Catherine, Sung Hyun Hwan, Jeong Byong Chang, Choi Han Yong, Kwon Ghee Young, Park Se Ho |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: